Additional prospective, diet-controlled clinical trials including 24,25-hydroxyvitamin D/25-hydroxyvitamin D ratio determination or genotyping for CYP24A1 should be performed to better investigate the role of mineral and bone derangements on the risk for kidney stones. This evidence concerns the gene CYP24A1 and nephrolithiasis.